Prevention of arthrofibrosis by monoclonal antibody against vascular endothelial growth factor: A novel use of bevacizumab in rabbits

Orthopaedics and Traumatology: Surgery and Research

Volumn 98, Issue 7, 2012, Pages 759-764

  Emami, M J ^a   Jaberi, F M ^a   Azarpira, N ^b   Vosoughi, A R ^a   Tanideh, N ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bevacizumab; Fibrosis; Induced arthrofibrosis; Joint; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; BUPRENORPHINE; CEFAZOLIN; KETAMINE; SODIUM CHLORIDE; VASCULOTROPIN; XYLAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHROFIBROSIS; ARTICLE; CONTROLLED STUDY; CORTICAL BONE; DISEASE SEVERITY; FEMUR CONDYLE; FIBROBLAST; FIBROSIS; GENERAL ANESTHESIA; GIANT CELL; GRANULATION TISSUE; HISTOPATHOLOGY; HYPERPLASIA; INFLAMMATORY CELL; JOINT; MALE; NONHUMAN; PRIORITY JOURNAL; RANGE OF MOTION; SCORING SYSTEM; SINGLE DRUG DOSE; SURGICAL TECHNIQUE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; HYPERPLASIA; INJECTIONS, INTRA-ARTICULAR; JOINT DISEASES; MALE; RABBITS; STIFLE;

EID: 84868346815     PISSN: None     EISSN: 18770568     Source Type: Journal    
DOI: 10.1016/j.otsr.2012.05.020     Document Type: Article

References (42)

1. Lindenfeld T.N., Wojtys E.M., Husain A. Surgical treatment of arthrofibrosis of the knee. Instr Course Lect 2000, 49:211-221.
2. Bosch U., Zeichen J., Skutek M., et al. Arthrofibrosis is the result of a T cell mediated immune response. Knee Surg Sports Traumatol Arthrosc 2001, 9:282-289.
3. Freeman T.A., Parvizi J., Dela Valle C.J., et al. Mast cells and hypoxia drive tissue metaplasia and heterotopic ossification in idiopathic arthrofibrosis after total knee arthroplasty. Fibrogenesis Tissue Repair 2010, 3:17.
4. Schiavone Panni A., Cerciello S., Vasso M., et al. Stiffness in total knee arthroplasty. J Orthop Trauma 2009, 10:111-118.
5. Eakin C.L. Knee arthrofibrosis: prevention and management of a potentially devastating condition. Phys Sports Med 2001, 29:31-42.
6. Kim D.H., Gill T.J., Millett P.J. Arthroscopic treatment of the arthrofibrotic knee. Arthroscopy 2004, 20:187-194.
7. Namazi H., Torabi S. Novel use of botulinum toxin to ameliorate arthrofibrosis: an experimental study in rabbits. Toxicol Pathol 2007, 35:715-718.
8. Plaas A., Li J., Riesco J., et al. Intra-articular injection of hyaluronan prevents cartilage erosion, periarticular fibrosis and mechanical allodynia and normalizes stance time in murine knee osteoarthritis. Arthritis Res Ther 2011, 13:R46.
9. Xu R.S., Hou C.L., Yin C.H., et al. Clinical study on chitosan in prevention of knee adhesion after patellar operation. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2002, 16:240-241.
10. Fukui N., Fukuda A., Kojima K., et al. Suppression of fibrous adhesion by proteoglycan decorin. J Orthop Res 2001, 19:456-462.
11. Miller J.A., Ferguson R.L., Powers D.L., et al. Efficacy of hyaluronic acid/nonsteroidal anti-inflammatory drug systems in preventing postsurgical tendon adhesions. J Biomed Mater Res 1997, 38:25-33.
12. Kocaoglu B., Akgun U., Nalbantoglu U., et al. Adhesion reduction after knee surgery in a rat model by mitomycin C. Knee Surg Sports Traumatol Arthrosc 2011, 19:94-98.
13. Ozgenel G.Y. The effects of a combination of hyaluronic and amniotic membrane on the formation of peritendinous adhesions after flexor tendon surgery in chickens. J Bone Joint Surg Br 2004, 86:301-307.
14. Emami M.J., Namazi H., Vosoughi A.R., Nezhad S.T., Oryan A., Mozaffarian K. Can enoxaparin prevent arthrofibrosis?. Int J Clin Pharmacol Ther 2012, 50(1):49-50.
15. Fukui N., Nakajima K., Tashiro T., et al. Neutralization of fibroblast growth factor-2 reduces intra-articular adhesions. Clin Orthop Relat Res 2001, 383:250-258.
16. Fukui N., Tashiro T., Hiraoka H., et al. Adhesion formation can be reduced by the suppression of transforming growth factor-beta1 activity. J Orthop Res 2000, 18:212-219.
17. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000, 11:617-624.
18. Ignjatovic D., Aasland K., Pettersen M., et al. Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions. Am J Surg 2010, 200:270-275.
19. Dong J., Grunstein J., Tejada M., et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004, 23:2800-2810.
20. Diamond M.P., El-Hammady E., Munkarah A., et al. Modulation of the expression of vascular endothelial growth factor in human fibroblasts. Fertil Steril 2005, 83:405-409.
21. Wiczyk H.P., Grow D.R., Adams L.A., et al. Pelvic adhesions contain sex steroid receptors and produce angiogenesis growth factors. Fertil Steril 1998, 69:511-516.
22. Rout U.K., Oommen K., Diamond M.P. Altered expressions of VEGF mRNA splice variants during progression of uterine-peritoneal adhesions in the rat. Am J Reprod Immunol 2000, 43:299-304.
23. Molinas C.R., Campo R., Dewerchin M., et al. Role of vascular endothelial growth factor and placental growth factor in basal adhesion formation and in carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice. Fertil Steril 2003, 80:803-811.
24. Matsuoka M., Ogata N., Minamino K., et al. Expression of pigment epithelium-derived factor and vascular endothelial growth factor in fibrovascular membranes from patients with proliferative diabetic retinopathy. Jpn J Ophthalmol 2006, 50:116-120.
25. Simler N.R., Brenchley P.E., Horrocks A.W., et al. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004, 59:581-585.
26. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
27. O'Neill E.C., Qin Q., Van Bergen N.J., et al. Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci 2010, 51:6524-6532.
28. Lee S.H., Leem H.S., Jeong S.M., et al. Bevacizumab accelerates corneal wound healing by inhibiting TGF-beta2 expression in alkali-burned mouse cornea. BMB Rep 2009, 42:800-805.
29. Afuwape A.O., Feldmann M., Paleolog E.M. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther 2003, 10:1950-1960.
30. Brunelli G., Longinotti C., Bertazzo C., et al. Adhesion reduction after knee surgery in a rabbit model by Hyaloglide, a hyaluronan derivative gel. J Orthop Res 2005, 23:1377-1382.
31. Roughan J.V., Flecknell P.A. Buprenorphine: a reappraisal of its antinociceptive effects and therapeutic use in alleviating postoperative pain in animals. Lab Anim 2002, 36(3):322-343.
32. Rothkopf D.M., Webb S., Szabo R.M., et al. An experimental model for the study of canine flexor tendon adhesions. J Hand Surg Am 1991, 16:694-700.
33. Frisbie D.D., Oxford J.T., Southwood L., et al. Early events in cartilage repair after subchondral bone microfracture. Clin Orthop 2003, 407:215-227.
34. Yan H., Yu C. Repair of full-thickness cartilage defects with cells of different origin in a rabbit model. Arthroscopy 2007, 23:178-187.
35. Bellini A., Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007, 87:858-870.
36. Schmidt M., Sun G., Stacey M.A., et al. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003, 171:380-389.
37. Molinas C.R., Binda M.M., Carmeliet P., et al. Role of vascular endothelial growth factor receptor 1 in basal adhesion formation and in carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in mice. Fertil Steril 2004, 82:1149-1153.
38. Saltzman A.K., Olson T.A., Mohanraj D., et al. Prevention of postoperative adhesions by an antibody to vascular permeability factor/vascular endothelial growth factor in a murine model. Am J Obstet Gynecol 1996, 174:1502-1506.
39. Chung E.J., Kang S.J., Koo J.S., et al. Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy. Yonsei Med J 2011, 52:151-157.
40. Mukherji S.K. Bevacizumab (Avastin). AJNR Am J Neuroradiol 2010, 31:235-236.
41. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005, 91:173-180.
42. Rezaeian F., Wettstein R., Egger J.F., et al. Erythropoietin-induced upregulation of endothelial nitric oxide synthase but not vascular endothelial growth factor prevents musculocutaneous tissue from ischemic damage. Lab Invest 2010, 90:40-51.